iRadimed (NASDAQ:IRMD) Hits New 52-Week High on Better-Than-Expected Earnings

Shares of iRadimed Corporation (NASDAQ:IRMD) reached a new 52-week high on Tuesday following a better than expected earnings announcement. The stock traded as high as $107.90 and last traded at $105.3820, with a volume of 17681 shares trading hands. The stock had previously closed at $95.97.

The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The firm had revenue of $22.69 million for the quarter, compared to analyst estimates of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS.

iRadimed Dividend Announcement

The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s dividend payout ratio is 41.21%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Roth Mkm set a $90.00 target price on shares of iRadimed in a research note on Friday, October 31st. Lake Street Capital reissued a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Zacks Research upgraded iRadimed to a “hold” rating in a report on Tuesday, November 4th. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.00.

Insider Activity at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $100.65, for a total value of $503,250.00. Following the transaction, the chief executive officer directly owned 2,262,500 shares of the company’s stock, valued at $227,720,625. This represents a 0.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO John Glenn sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the transaction, the chief financial officer owned 7,362 shares in the company, valued at $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 55,000 shares of company stock worth $5,287,900 in the last ninety days. 36.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. FourThought Financial Partners LLC acquired a new stake in shares of iRadimed in the fourth quarter valued at approximately $448,000. Global Retirement Partners LLC bought a new position in iRadimed during the 4th quarter worth $85,000. Baader Bank Aktiengesellschaft bought a new position in iRadimed during the 4th quarter worth $595,000. Ballentine Partners LLC acquired a new position in iRadimed in the 4th quarter valued at $211,000. Finally, RFG Advisory LLC acquired a new stake in shares of iRadimed during the 4th quarter worth $1,594,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Stock Up 10.9%

The stock has a 50 day moving average of $97.82 and a 200 day moving average of $83.09. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of 64.52 and a beta of 1.11.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.